StreetInsider.com News Articles

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 -0400

Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology, AI-enabled drug development, and advanced drug delivery platforms, yesterday filed financial results for the quarter ended March 31, 2026 through its Quarterly Report on Form 10-Q, and is providing a corporate update highlighting progress across its therapeutic and platform initiatives.

“We believe the first quarter of 2026 continues to provide validation for the strategic value of our diversified biotechnology platform,” said Dr. Vuong Trieu, CEO of Oncotelic. “During the quarter,

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 -0400

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 -0400

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 -0400

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 -0400

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 -0400

NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations

Fri, 15 May 2026 08:30:00 -0400

AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities,” featuring Oncotelic Therapeutics Inc (OTCQB: OTLC).

To hear the NetworkNewsAudio version, visit https://nnw.fm/1QMGZ

To read the original editorial, visit: https://nnw.fm/pTi7i

The blood-brain barrier is a highly selective membrane that protects the brain from toxins and pathogens circulating in the bloodstream. While essential for survival, it also presents a formidable obstacle for therapeutic development.

NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations

Fri, 15 May 2026 08:30:00 -0400

To hear the NetworkNewsAudio version, visit https://nnw.fm/1QMGZ

To read the original editorial, visit: https://nnw.fm/pTi7i

NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations

Fri, 15 May 2026 08:30:00 -0400

To hear the NetworkNewsAudio version, visit https://nnw.fm/1QMGZ

To read the original editorial, visit: https://nnw.fm/pTi7i

NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations

Fri, 15 May 2026 08:30:00 -0400

To hear the NetworkNewsAudio version, visit https://nnw.fm/1QMGZ

To read the original editorial, visit: https://nnw.fm/pTi7i

Form 10-Q Oncotelic Therapeutics, For: Mar 31

Thu, 14 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26496661.html

Form 10-Q Oncotelic Therapeutics, For: Mar 31

Thu, 14 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26496661.html

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

Thu, 14 May 2026 08:30:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research,” please visit:

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

Thu, 14 May 2026 08:30:00 -0400

To view the full publication, “CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research,” please visit:

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

Thu, 14 May 2026 08:30:00 -0400

To view the full publication, “CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research,” please visit:

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

Thu, 14 May 2026 08:30:00 -0400

To view the full publication, “CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research,” please visit:

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research